Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.
NCT ID: NCT00337493
Last Updated: 2012-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
155 participants
INTERVENTIONAL
2005-12-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
mycophenolate mofetil [CellCept]
Concentration-controlled
Cyclosporine or tacrolimus
Reduced
2
mycophenolate mofetil [CellCept]
Concentration-controlled
Cyclosporine or tacrolimus
Standard, as prescribed
3
mycophenolate mofetil [CellCept]
1g po bid
Cyclosporine or tacrolimus
Standard, as prescribed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mycophenolate mofetil [CellCept]
Concentration-controlled
mycophenolate mofetil [CellCept]
1g po bid
Cyclosporine or tacrolimus
Reduced
Cyclosporine or tacrolimus
Standard, as prescribed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
13 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Denver, Colorado, United States
Gainesville, Florida, United States
Orlando, Florida, United States
Augusta, Georgia, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Lexington, Kentucky, United States
Shreveport, Louisiana, United States
Boston, Massachusetts, United States
Hackensack, New Jersey, United States
Livingston, New Jersey, United States
Buffalo, New York, United States
Chapel Hill, North Carolina, United States
Fargo, North Dakota, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML19199
Identifier Type: -
Identifier Source: org_study_id